综述/Review article视网膜神经血管单元自噬:糖尿病视网膜病变的新视角Autophagy in the retinal neurovascular unit:New perspectives into diabetic retinopathy Xiongyi Yang1,2,Zexin Huang1,2,Mei Xu3,Yanxia Chen4,Mingzhe Cao5...综述/Review article视网膜神经血管单元自噬:糖尿病视网膜病变的新视角Autophagy in the retinal neurovascular unit:New perspectives into diabetic retinopathy Xiongyi Yang1,2,Zexin Huang1,2,Mei Xu3,Yanxia Chen4,Mingzhe Cao5,Guoguo Yi6,Min Fu41Zhujiang Hospital,Southern Medical University,Guangzhou,Guangdong,P.R.China;2The Second Clinical School,Southern Medical University,Guangzhou,Guangdong,P.R.China;3The Second People′s Hospital of Jingmen,Jingmen,Hubei,People′s Republic of China;4Department of Ophthalmology,Zhujiang Hospital,Southern Medical University,Guangzhou,Guangdong,P.R.China;5Department of Ophthalmology,The Seventh Affiliated Hospital,Sun Yat-Sen University,Shenzhen,P.R.China;6Department of Ophthalmology,The Sixth Affiliated Hospital,Sun Yat-Sen University,Guangzhou,Guangdong,P.R.China【摘要】糖尿病视网膜病变(DR)是世界范围内最常见的视网膜疾病之一,是育龄人群视力损害的主要原因。研究表明,自噬是破坏和恢复胞质成分所需的一种重要的细胞内稳态机制,在DR中具有重要意义。自噬维持应激状态下衰老和受损细胞器的生理功能,从而通过多种信号调节细胞寿命。视网膜神经血管单元(NVU)作为视网膜的基本功能单位,在维持视网膜环境稳定和支持视网膜代谢需求方面起着至关重要的作用。然而,自噬对于NVU的正常结构和功能至关重要。本文就DR与自噬的密切关系、自噬的种类及其在视网膜中的重要生理活性进行综述。期望通过评估DR中视网膜NVU的病理变化以及自噬可能参与NVU中DR病理生理分子机制的最新进展,寻求防治DR的新思路和方法。展开更多
综述/Review Article。microRNA对各种糖尿病创面局部细胞的作用及机制。Effect and mechanism of microRNAs on various diabetic wound local cells。Hongjie Li,Shengyu Jing Central South University Xiangya School of Medicine,C...综述/Review Article。microRNA对各种糖尿病创面局部细胞的作用及机制。Effect and mechanism of microRNAs on various diabetic wound local cells。Hongjie Li,Shengyu Jing Central South University Xiangya School of Medicine,Changsha,Hunan Province,China。展开更多
综述/Review article糖尿病足溃疡发生机制综述Mechanisms of Diabetic Foot Ulceration:A Review Haibo Deng1,Binghui Li1,Qian Shen3,Chenchen Zhang1,Liwen Kuang1,Ran Chen1,Siyuan Wang1,Zhiqiang Ma1,Gongchi Li21Department of ...综述/Review article糖尿病足溃疡发生机制综述Mechanisms of Diabetic Foot Ulceration:A Review Haibo Deng1,Binghui Li1,Qian Shen3,Chenchen Zhang1,Liwen Kuang1,Ran Chen1,Siyuan Wang1,Zhiqiang Ma1,Gongchi Li21Department of Wound Repair,Liyuan Hospital Affiliated to Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei,430077,China;2Department of Hand Surgery,Union Hospital Affiliated to Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei,430022,China;3School of Foreign Studies,Zhongnan University of Economics and Law,Wuhan,Hubei,430073,China【摘要】糖尿病足溃疡(DFUs)与复杂的病理因素有关,被认为是糖尿病的严重并发症。目前,潜在的DFUs机制已经越来越受到研究关注。以往的研究主要集中在糖尿病周围血管疾病、神经病变和创伤感染三个方面。随着技术的进步,研究人员逐渐开始使用免疫细胞、内皮细胞、角质细胞和成纤维细胞进行研究,因为它们参与了创伤愈合过程。报道称,分子信号通路的上调或下调对DFUs的愈合至关重要。随着对表观遗传学认识的增强,其在创伤愈合中的调控作用成为治疗DFUs的热门趋势。本综述关注DFUs发病机制涉及的四个方面:生理和病理机制、细胞机制、分子信号通路机制和表观遗传学。鉴于DFUs治疗的挑战,我们希望本综述能为同行提供新思路。展开更多
综述/Review Article miRNAs在2型糖尿病人类和动物中的变化A review of micro RNAs changes in T2DM in animals and humans Mohammad Reza Afsharmanesh1,2,Zeinab Mohammadi1,2,Azad Rexa Mansourian1,2,Seyyed Mehdi Jafari1,21Meta...综述/Review Article miRNAs在2型糖尿病人类和动物中的变化A review of micro RNAs changes in T2DM in animals and humans Mohammad Reza Afsharmanesh1,2,Zeinab Mohammadi1,2,Azad Rexa Mansourian1,2,Seyyed Mehdi Jafari1,21Metabolic Disorders Research Center,Golestan University of Medical Sciences,Gorgan,Iran;2Department of Biochemistry and Biophysics,School of Medicine,Golestan University of Medical Sciences,Gorgan,Iran.[摘要]2型糖尿病及其相关并发症已成为全球重要的公共卫生问题。根据现有文献,慢性炎症与2型糖尿病的进展有密切关系。越来越多的证据表明,炎症增强了胰岛素分泌功能的丧失和靶组织对胰岛素作用的抵抗,这是2型糖尿病发展的两个关键特征。展开更多
综述/Review Article糖尿病的发育起源:环境表观基因组学和新模式Developmental Origins of Diabetes Mellitus:environmental epigenomics and emerging patterns Hong Zhu1,2,Guolian Ding1,2,Xinmei Liu1,2,Hefeng Huang1,2,3,41Obst...综述/Review Article糖尿病的发育起源:环境表观基因组学和新模式Developmental Origins of Diabetes Mellitus:environmental epigenomics and emerging patterns Hong Zhu1,2,Guolian Ding1,2,Xinmei Liu1,2,Hefeng Huang1,2,3,41Obstetrics and Gynecology Hospital,Institute of Reproduction and Development,Fudan University,Shanghai 200011,China;2Research Units of Embryo Original Diseases,Chinese Academy of Medical Sciences,Shanghai 200030,China;3Key Laboratory of Reproductive Genetics(Ministry of Education),Zhejiang University School of Medicine,Hangzhou,310006,China;4Shanghai Key Laboratory of Embryo Original Diseases,Shanghai 200030,China【摘要】越来越多的流行病学证据表明,生命早期的环境暴露与后期糖尿病易感性有关。此外,环境诱导的糖尿病易感性可遗传给后代。表观遗传修饰提供了与环境因素和可能导致疾病表型的基因表达改变的潜在关联。在本文中,我们梳理了越来越多的证据,表明发育早期的环境暴露与糖尿病通过表观遗传修饰相关。本文首先总结了环境因素通过亚稳态表观等位基因和印记基因等表观遗传靶点来修饰表观基因组。然后,以糖尿病易感性为例,概述了表观遗传学在关键发育时间窗、配子发生、胚胎发生、胎儿期和出生后阶段响应环境挑战的变化。虽然其机制仍有很大部分未知,尤其是在人类中,但新的研究方法正在逐步出现,动物模型的策略可以实现对机制的更深入研究。这对研究这些现象与人类糖尿病之间的联系具有意义,为环境触发的糖尿病风险提供了一个新的视角。展开更多
综述/Review Article 2型糖尿病患者的β细胞功能:能被保留或增强吗?Beta-cell function in type 2 diabetes(T2DM):can it be preserved or enhanced?Laure Sayyed Kassem1,2,Aman Rajpal1,2,Margarita Barreiro1,3,and Faramarz Ismai...综述/Review Article 2型糖尿病患者的β细胞功能:能被保留或增强吗?Beta-cell function in type 2 diabetes(T2DM):can it be preserved or enhanced?Laure Sayyed Kassem1,2,Aman Rajpal1,2,Margarita Barreiro1,3,and Faramarz Ismail-Beigi1,2,31Case Western Reserve University,2Cleveland VA Medical Center,and3University Hospitals of Cleveland【摘要】2型糖尿病(T2DM)是一种复杂的代谢紊乱,表现为高血糖、胰岛素抵抗和β细胞功能逐渐恶化。预防该疾病进展的一种方法是增强β细胞功能和胰岛素分泌。然而,此前大多数研究在患者使用降糖药物且没有足够的时间停药(洗脱期)的情况下检查了β细胞功能。在本文中,我们重点讨论了有洗脱期的研究。我们使用了β细胞功能和增强作为关键词进行了文献检索(2010年至2021年6月)。现有证据表明,β细胞功能可以增强。减重手术和极低热量饮食可改善许多个体的β细胞功能。此外,使用GLP-1受体激动剂进行长期治疗(3年或更长时间)也可以改善β细胞功能。需要进一步的研究来了解导致改善β细胞功能的机制,并确定可以增强T2DM患者β细胞功能的药物。展开更多
综述/Review Article,健康素养干预对2型糖尿病患者血糖控制和自我管理结果的影响:一项系统综述,The impact of health literacy interventions on glycemic control and self-management outcomes among type 2 diabetes mellitus:a sy...综述/Review Article,健康素养干预对2型糖尿病患者血糖控制和自我管理结果的影响:一项系统综述,The impact of health literacy interventions on glycemic control and self-management outcomes among type 2 diabetes mellitus:a systematic review Jamila Butayeva1,Zubair Ahmed Ratan1,Sue Downie2,Hassan Hosseinzadeh1,1School of Health&Society,Faculty of the Arts,Social Sciences and Humanities,University of Wollongong,Wollongong,New South Wales,Australia;2Discipline of Medical and Exercise Science,Faculty of Science,Medicine and Health,School of Medicine,University of Wollongong,Wollongong,New South Wales,Australia.展开更多
综述/Review Article使用基础胰岛素治疗成人2型糖尿病:亚太地区循证临床实践指南Use of basal insulin in the management of adults with type 2 diabetes:an Asia-Pacific evidence-based clinical practice guideline Linong Ji1,Yi...综述/Review Article使用基础胰岛素治疗成人2型糖尿病:亚太地区循证临床实践指南Use of basal insulin in the management of adults with type 2 diabetes:an Asia-Pacific evidence-based clinical practice guideline Linong Ji1,Yingying Luo1,Yong Mong Bee2,Jun Xia3,4,Nguyen Khue Thy5,Weigang Zhao6,Liming Chen7,Siew Pheng Chan8,Chaicharn Deerochanawong9,Soo Lim10,Daisuke Yabe11,12,Margaret McGill13,Ketut Suastika14,Xiaoying Li15,Alice Pik Shan Kong16,Wei Chen17,Zhan Zhao18,Chenchen Xu18,Marisa Deodat19,Xiaomei Yao20,211Department of Endocrinology and Metabolism,Peking University People′s Hospital,Beijing,100044,China;2Department of Endocrinology,Singapore General Hospital,169608,Singapore;3Nottingham Ningbo GRADE Centre,University of Nottingham Ningbo China,Ningbo,Zhejiang,315100,China;4Academic Unit of Lifespan and Population Health,School of Medicine,The University of Nottingham,Nottingham,NG72UH,UK;5Ho Chi Minh University of Medicine and Pharmacy Medic Medical Center,Ho Chi Minh City,700000,Vietnam;6Department of Endocrinology,Peking Union Medical College Hospital,Beijing,100730,China;7Chu Hsien-I Memorial(Metabolic Diseases)Hospital&Tianjin Institute of Endocrinology,Tianjin Medical University,Tianjin,300134,China;8Department of Medicine,Faculty of Medicine,University of Malaya,Lembah Pantai 59100 Kuala Lumpur,Malaysia;9College of Medicine,Rangsit University,Bangkok,10400,Thailand;10Department of Internal Medicine,Seoul National University College of Medicine and Seoul National University Bundang Hospital,Seongnam,13620,South Korea;11Departments of Diabetes,Endocrinology and Metabolism/Rheumatology and Clinical Immunology,Gifu University Graduate School of Medicine,Gifu,501-1194,Japan;12Center for One Medicine Innovative Translational Research,Gifu University Institute for Advanced Study,Gifu,501-1194,Japan;13Diabetes Centre,Royal Prince Alfred Hospital,Faculty of Medicine and Health University of Sydney,Sydney,New South Wales,2050,Australia;14Division of Endocrinology and Metabolism,Department of Internal Medicine,Faculty of Medicine,Udayana University,Prof.IGNG Ngoerah Hospital,Denpasar,Bali,80114,Indonesia;15Department of Endocrinology and Metabolism,Zhongshan Hospital,Fudan University,Shanghai,200032,China;16Division of Endocrinology,Department of Medicine and Therapeutics,The Chinese University of Hong Kong,Hong Kong Special Administrative Region,999077,China;17Department of Clinical Nutrition,Department of Health Medicine,Chinese Academy of Medical Sciences-Peking Union Medical College,Peking Union Medical College Hospital,Beijing,100730,China;18Tianjin Tiantian Biotechnology Co.,Ltd.Tianjin,300000,China;19Michael G.DeGroote Cochrane Canada and McMaster GRADE Centres,McMaster University,Hamilton,Ontario,L8V 5C2,Canada;20Center for Clinical Practice Guideline Conduction and Evaluation,Children′s Hospital of Fudan University,Shanghai,201100,China;21Department of Health Research Methods,Evidence,and Impact,McMaster University,Hamilton,Ontario,L8V 5C2,Canada【提要】为亚太地区初次使用胰岛素的成人2型糖尿病患者提供关于5种基础胰岛素(甘精胰岛素U-300、德谷胰岛素U-100、甘精胰岛素U-100型、地特胰岛素和中性鱼精蛋白胰岛素)的有效性、安全性、最佳起始剂量、最佳维持剂量范围和目标空腹血浆葡萄糖的推荐。基于系统回顾的证据,本综述通过全面的内部审核和外部审核流程制定了亚太地区临床实践指南。本综述在整体证据确定性评估中为不同重要和关键结局设置了微小、小、中等和大效应的临床阈值,并遵循GRADE(评估、发展、评价、建议的分级)方法来平衡干预效果的大小以进行推荐。本综述遵守了AGREE(指南评估、研究和评估)和RIGHT(卫生保健实践指南报告项目)指南报告检查清单。在工作组成员进行第二轮投票后,所有推荐和限定性陈述的一致率均达到了75%以上。在联系的44名外部评审人员中,本研究收到了33名临床医生和1例患者的意见,总体应答率为77%。为解决4个研究问题,本研究提出了2个强烈推荐、6个有条件推荐和2个限定性陈述。尽管本指南的预期用户主要是亚太地区的临床医生,但所选的证据基于最近的英文出版物。本综述提示,指南中制定的推荐和临床阈值可以成为全球关注2型糖尿病患者的临床医生的参考。展开更多
论著/Original Article COVID-19大流行期间1型糖尿病儿童和年轻人心血管危险因素与往年相比的变化——来自德国糖尿病患者随访登记(DPV)的结果Changes in cardiovascular risk factors among children and young adults with type 1 di...论著/Original Article COVID-19大流行期间1型糖尿病儿童和年轻人心血管危险因素与往年相比的变化——来自德国糖尿病患者随访登记(DPV)的结果Changes in cardiovascular risk factors among children and young adults with type 1 diabetes during the COVID-19 pandemic compared to previous years-Results from the German DPV registry Alexander J.Eckert1,2,Sabine Linke3,Karl-Otfried Schwab4,Thekla von dem Berge5,Eckhard Schönau6,Ibrahim Duran7,Axel Dost8,Christine Joisten9,10,Heike Bartelt11,Katarina Braune12,13,14,Joachim Rosenbauer2,15,Reinhard W.Holl1,2.展开更多
文摘综述/Review article视网膜神经血管单元自噬:糖尿病视网膜病变的新视角Autophagy in the retinal neurovascular unit:New perspectives into diabetic retinopathy Xiongyi Yang1,2,Zexin Huang1,2,Mei Xu3,Yanxia Chen4,Mingzhe Cao5,Guoguo Yi6,Min Fu41Zhujiang Hospital,Southern Medical University,Guangzhou,Guangdong,P.R.China;2The Second Clinical School,Southern Medical University,Guangzhou,Guangdong,P.R.China;3The Second People′s Hospital of Jingmen,Jingmen,Hubei,People′s Republic of China;4Department of Ophthalmology,Zhujiang Hospital,Southern Medical University,Guangzhou,Guangdong,P.R.China;5Department of Ophthalmology,The Seventh Affiliated Hospital,Sun Yat-Sen University,Shenzhen,P.R.China;6Department of Ophthalmology,The Sixth Affiliated Hospital,Sun Yat-Sen University,Guangzhou,Guangdong,P.R.China【摘要】糖尿病视网膜病变(DR)是世界范围内最常见的视网膜疾病之一,是育龄人群视力损害的主要原因。研究表明,自噬是破坏和恢复胞质成分所需的一种重要的细胞内稳态机制,在DR中具有重要意义。自噬维持应激状态下衰老和受损细胞器的生理功能,从而通过多种信号调节细胞寿命。视网膜神经血管单元(NVU)作为视网膜的基本功能单位,在维持视网膜环境稳定和支持视网膜代谢需求方面起着至关重要的作用。然而,自噬对于NVU的正常结构和功能至关重要。本文就DR与自噬的密切关系、自噬的种类及其在视网膜中的重要生理活性进行综述。期望通过评估DR中视网膜NVU的病理变化以及自噬可能参与NVU中DR病理生理分子机制的最新进展,寻求防治DR的新思路和方法。
文摘综述/Review Article。microRNA对各种糖尿病创面局部细胞的作用及机制。Effect and mechanism of microRNAs on various diabetic wound local cells。Hongjie Li,Shengyu Jing Central South University Xiangya School of Medicine,Changsha,Hunan Province,China。
文摘综述/Review article糖尿病足溃疡发生机制综述Mechanisms of Diabetic Foot Ulceration:A Review Haibo Deng1,Binghui Li1,Qian Shen3,Chenchen Zhang1,Liwen Kuang1,Ran Chen1,Siyuan Wang1,Zhiqiang Ma1,Gongchi Li21Department of Wound Repair,Liyuan Hospital Affiliated to Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei,430077,China;2Department of Hand Surgery,Union Hospital Affiliated to Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei,430022,China;3School of Foreign Studies,Zhongnan University of Economics and Law,Wuhan,Hubei,430073,China【摘要】糖尿病足溃疡(DFUs)与复杂的病理因素有关,被认为是糖尿病的严重并发症。目前,潜在的DFUs机制已经越来越受到研究关注。以往的研究主要集中在糖尿病周围血管疾病、神经病变和创伤感染三个方面。随着技术的进步,研究人员逐渐开始使用免疫细胞、内皮细胞、角质细胞和成纤维细胞进行研究,因为它们参与了创伤愈合过程。报道称,分子信号通路的上调或下调对DFUs的愈合至关重要。随着对表观遗传学认识的增强,其在创伤愈合中的调控作用成为治疗DFUs的热门趋势。本综述关注DFUs发病机制涉及的四个方面:生理和病理机制、细胞机制、分子信号通路机制和表观遗传学。鉴于DFUs治疗的挑战,我们希望本综述能为同行提供新思路。
文摘综述/Review Article miRNAs在2型糖尿病人类和动物中的变化A review of micro RNAs changes in T2DM in animals and humans Mohammad Reza Afsharmanesh1,2,Zeinab Mohammadi1,2,Azad Rexa Mansourian1,2,Seyyed Mehdi Jafari1,21Metabolic Disorders Research Center,Golestan University of Medical Sciences,Gorgan,Iran;2Department of Biochemistry and Biophysics,School of Medicine,Golestan University of Medical Sciences,Gorgan,Iran.[摘要]2型糖尿病及其相关并发症已成为全球重要的公共卫生问题。根据现有文献,慢性炎症与2型糖尿病的进展有密切关系。越来越多的证据表明,炎症增强了胰岛素分泌功能的丧失和靶组织对胰岛素作用的抵抗,这是2型糖尿病发展的两个关键特征。
文摘综述/Review Article糖尿病的发育起源:环境表观基因组学和新模式Developmental Origins of Diabetes Mellitus:environmental epigenomics and emerging patterns Hong Zhu1,2,Guolian Ding1,2,Xinmei Liu1,2,Hefeng Huang1,2,3,41Obstetrics and Gynecology Hospital,Institute of Reproduction and Development,Fudan University,Shanghai 200011,China;2Research Units of Embryo Original Diseases,Chinese Academy of Medical Sciences,Shanghai 200030,China;3Key Laboratory of Reproductive Genetics(Ministry of Education),Zhejiang University School of Medicine,Hangzhou,310006,China;4Shanghai Key Laboratory of Embryo Original Diseases,Shanghai 200030,China【摘要】越来越多的流行病学证据表明,生命早期的环境暴露与后期糖尿病易感性有关。此外,环境诱导的糖尿病易感性可遗传给后代。表观遗传修饰提供了与环境因素和可能导致疾病表型的基因表达改变的潜在关联。在本文中,我们梳理了越来越多的证据,表明发育早期的环境暴露与糖尿病通过表观遗传修饰相关。本文首先总结了环境因素通过亚稳态表观等位基因和印记基因等表观遗传靶点来修饰表观基因组。然后,以糖尿病易感性为例,概述了表观遗传学在关键发育时间窗、配子发生、胚胎发生、胎儿期和出生后阶段响应环境挑战的变化。虽然其机制仍有很大部分未知,尤其是在人类中,但新的研究方法正在逐步出现,动物模型的策略可以实现对机制的更深入研究。这对研究这些现象与人类糖尿病之间的联系具有意义,为环境触发的糖尿病风险提供了一个新的视角。
文摘综述/Review Article 2型糖尿病患者的β细胞功能:能被保留或增强吗?Beta-cell function in type 2 diabetes(T2DM):can it be preserved or enhanced?Laure Sayyed Kassem1,2,Aman Rajpal1,2,Margarita Barreiro1,3,and Faramarz Ismail-Beigi1,2,31Case Western Reserve University,2Cleveland VA Medical Center,and3University Hospitals of Cleveland【摘要】2型糖尿病(T2DM)是一种复杂的代谢紊乱,表现为高血糖、胰岛素抵抗和β细胞功能逐渐恶化。预防该疾病进展的一种方法是增强β细胞功能和胰岛素分泌。然而,此前大多数研究在患者使用降糖药物且没有足够的时间停药(洗脱期)的情况下检查了β细胞功能。在本文中,我们重点讨论了有洗脱期的研究。我们使用了β细胞功能和增强作为关键词进行了文献检索(2010年至2021年6月)。现有证据表明,β细胞功能可以增强。减重手术和极低热量饮食可改善许多个体的β细胞功能。此外,使用GLP-1受体激动剂进行长期治疗(3年或更长时间)也可以改善β细胞功能。需要进一步的研究来了解导致改善β细胞功能的机制,并确定可以增强T2DM患者β细胞功能的药物。
文摘综述/Review Article,健康素养干预对2型糖尿病患者血糖控制和自我管理结果的影响:一项系统综述,The impact of health literacy interventions on glycemic control and self-management outcomes among type 2 diabetes mellitus:a systematic review Jamila Butayeva1,Zubair Ahmed Ratan1,Sue Downie2,Hassan Hosseinzadeh1,1School of Health&Society,Faculty of the Arts,Social Sciences and Humanities,University of Wollongong,Wollongong,New South Wales,Australia;2Discipline of Medical and Exercise Science,Faculty of Science,Medicine and Health,School of Medicine,University of Wollongong,Wollongong,New South Wales,Australia.
文摘综述/Review Article使用基础胰岛素治疗成人2型糖尿病:亚太地区循证临床实践指南Use of basal insulin in the management of adults with type 2 diabetes:an Asia-Pacific evidence-based clinical practice guideline Linong Ji1,Yingying Luo1,Yong Mong Bee2,Jun Xia3,4,Nguyen Khue Thy5,Weigang Zhao6,Liming Chen7,Siew Pheng Chan8,Chaicharn Deerochanawong9,Soo Lim10,Daisuke Yabe11,12,Margaret McGill13,Ketut Suastika14,Xiaoying Li15,Alice Pik Shan Kong16,Wei Chen17,Zhan Zhao18,Chenchen Xu18,Marisa Deodat19,Xiaomei Yao20,211Department of Endocrinology and Metabolism,Peking University People′s Hospital,Beijing,100044,China;2Department of Endocrinology,Singapore General Hospital,169608,Singapore;3Nottingham Ningbo GRADE Centre,University of Nottingham Ningbo China,Ningbo,Zhejiang,315100,China;4Academic Unit of Lifespan and Population Health,School of Medicine,The University of Nottingham,Nottingham,NG72UH,UK;5Ho Chi Minh University of Medicine and Pharmacy Medic Medical Center,Ho Chi Minh City,700000,Vietnam;6Department of Endocrinology,Peking Union Medical College Hospital,Beijing,100730,China;7Chu Hsien-I Memorial(Metabolic Diseases)Hospital&Tianjin Institute of Endocrinology,Tianjin Medical University,Tianjin,300134,China;8Department of Medicine,Faculty of Medicine,University of Malaya,Lembah Pantai 59100 Kuala Lumpur,Malaysia;9College of Medicine,Rangsit University,Bangkok,10400,Thailand;10Department of Internal Medicine,Seoul National University College of Medicine and Seoul National University Bundang Hospital,Seongnam,13620,South Korea;11Departments of Diabetes,Endocrinology and Metabolism/Rheumatology and Clinical Immunology,Gifu University Graduate School of Medicine,Gifu,501-1194,Japan;12Center for One Medicine Innovative Translational Research,Gifu University Institute for Advanced Study,Gifu,501-1194,Japan;13Diabetes Centre,Royal Prince Alfred Hospital,Faculty of Medicine and Health University of Sydney,Sydney,New South Wales,2050,Australia;14Division of Endocrinology and Metabolism,Department of Internal Medicine,Faculty of Medicine,Udayana University,Prof.IGNG Ngoerah Hospital,Denpasar,Bali,80114,Indonesia;15Department of Endocrinology and Metabolism,Zhongshan Hospital,Fudan University,Shanghai,200032,China;16Division of Endocrinology,Department of Medicine and Therapeutics,The Chinese University of Hong Kong,Hong Kong Special Administrative Region,999077,China;17Department of Clinical Nutrition,Department of Health Medicine,Chinese Academy of Medical Sciences-Peking Union Medical College,Peking Union Medical College Hospital,Beijing,100730,China;18Tianjin Tiantian Biotechnology Co.,Ltd.Tianjin,300000,China;19Michael G.DeGroote Cochrane Canada and McMaster GRADE Centres,McMaster University,Hamilton,Ontario,L8V 5C2,Canada;20Center for Clinical Practice Guideline Conduction and Evaluation,Children′s Hospital of Fudan University,Shanghai,201100,China;21Department of Health Research Methods,Evidence,and Impact,McMaster University,Hamilton,Ontario,L8V 5C2,Canada【提要】为亚太地区初次使用胰岛素的成人2型糖尿病患者提供关于5种基础胰岛素(甘精胰岛素U-300、德谷胰岛素U-100、甘精胰岛素U-100型、地特胰岛素和中性鱼精蛋白胰岛素)的有效性、安全性、最佳起始剂量、最佳维持剂量范围和目标空腹血浆葡萄糖的推荐。基于系统回顾的证据,本综述通过全面的内部审核和外部审核流程制定了亚太地区临床实践指南。本综述在整体证据确定性评估中为不同重要和关键结局设置了微小、小、中等和大效应的临床阈值,并遵循GRADE(评估、发展、评价、建议的分级)方法来平衡干预效果的大小以进行推荐。本综述遵守了AGREE(指南评估、研究和评估)和RIGHT(卫生保健实践指南报告项目)指南报告检查清单。在工作组成员进行第二轮投票后,所有推荐和限定性陈述的一致率均达到了75%以上。在联系的44名外部评审人员中,本研究收到了33名临床医生和1例患者的意见,总体应答率为77%。为解决4个研究问题,本研究提出了2个强烈推荐、6个有条件推荐和2个限定性陈述。尽管本指南的预期用户主要是亚太地区的临床医生,但所选的证据基于最近的英文出版物。本综述提示,指南中制定的推荐和临床阈值可以成为全球关注2型糖尿病患者的临床医生的参考。
文摘论著/Original Article COVID-19大流行期间1型糖尿病儿童和年轻人心血管危险因素与往年相比的变化——来自德国糖尿病患者随访登记(DPV)的结果Changes in cardiovascular risk factors among children and young adults with type 1 diabetes during the COVID-19 pandemic compared to previous years-Results from the German DPV registry Alexander J.Eckert1,2,Sabine Linke3,Karl-Otfried Schwab4,Thekla von dem Berge5,Eckhard Schönau6,Ibrahim Duran7,Axel Dost8,Christine Joisten9,10,Heike Bartelt11,Katarina Braune12,13,14,Joachim Rosenbauer2,15,Reinhard W.Holl1,2.
